Lipella Pharmaceuticals Inc. developed novel therapies using liposomal drug delivery technology and advanced multiple drug candidates into clinical trials. Lipella completed its initial public offering in 2022, and its common stock began trading on the Nasdaq Capital Market. The Company reported Phase 2 results in hemorrhagic cystitis and oral lichen planus.
Following financing difficulties in 2025, Lipella filed for Chapter 11 bankruptcy protection in March 2026. In June 2026, the Company completed a court-approved sale of its clinical development programs, intellectual property, and regulatory assets to XRAIY LLC. The acquired programs are now being pursued under the Kube Biosciences name.
Disclosure Statement and Chapter 11 Plan of Liquidation — View Document
Email: info@lipella.com
© 2026 Lipella Pharmaceuticals Inc.